Intrinsic value of Accelerate Diagnostics - AXDX

Previous Close

$14.44

  Intrinsic Value

$0.58

stock screener

  Rating & Target

str. sell

-96%

Previous close

$14.44

 
Intrinsic value

$0.58

 
Up/down potential

-96%

 
Rating

str. sell

We calculate the intrinsic value of AXDX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  7
  10
  15
  22
  32
  43
  58
  77
  99
  124
  155
  189
  228
  271
  319
  371
  427
  488
  552
  621
  693
  770
  850
  934
  1,022
  1,113
  1,208
  1,307
  1,410
  1,517
Variable operating expenses, $m
  363
  560
  838
  1,215
  1,715
  2,357
  3,164
  4,155
  5,346
  6,753
  8,386
  10,252
  12,358
  14,703
  17,288
  20,110
  23,165
  26,448
  29,954
  33,677
  37,613
  41,758
  46,107
  50,660
  55,416
  60,374
  65,538
  70,912
  76,498
  82,305
Fixed operating expenses, $m
  56
  57
  59
  60
  61
  63
  64
  65
  67
  68
  70
  71
  73
  75
  76
  78
  80
  81
  83
  85
  87
  89
  91
  93
  95
  97
  99
  101
  103
  106
Total operating expenses, $m
  419
  617
  897
  1,275
  1,776
  2,420
  3,228
  4,220
  5,413
  6,821
  8,456
  10,323
  12,431
  14,778
  17,364
  20,188
  23,245
  26,529
  30,037
  33,762
  37,700
  41,847
  46,198
  50,753
  55,511
  60,471
  65,637
  71,013
  76,601
  82,411
Operating income, $m
  -412
  -607
  -881
  -1,253
  -1,745
  -2,377
  -3,170
  -4,144
  -5,315
  -6,697
  -8,301
  -10,135
  -12,203
  -14,507
  -17,046
  -19,817
  -22,818
  -26,042
  -29,485
  -33,142
  -37,007
  -41,077
  -45,348
  -49,819
  -54,489
  -59,358
  -64,429
  -69,705
  -75,191
  -80,893
EBITDA, $m
  -411
  -605
  -877
  -1,248
  -1,737
  -2,367
  -3,157
  -4,126
  -5,292
  -6,668
  -8,265
  -10,091
  -12,150
  -14,444
  -16,972
  -19,731
  -22,719
  -25,929
  -29,357
  -32,997
  -36,846
  -40,898
  -45,150
  -49,602
  -54,252
  -59,100
  -64,149
  -69,402
  -74,864
  -80,541
Interest expense (income), $m
  0
  0
  0
  1
  1
  2
  3
  4
  5
  7
  9
  11
  14
  17
  21
  25
  29
  34
  39
  44
  50
  57
  63
  70
  78
  85
  93
  102
  111
  120
  129
Earnings before tax, $m
  -412
  -608
  -882
  -1,254
  -1,746
  -2,379
  -3,174
  -4,149
  -5,321
  -6,706
  -8,312
  -10,149
  -12,220
  -14,527
  -17,070
  -19,846
  -22,852
  -26,081
  -29,530
  -33,192
  -37,063
  -41,140
  -45,418
  -49,896
  -54,574
  -59,452
  -64,531
  -69,816
  -75,311
  -81,022
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -412
  -608
  -882
  -1,254
  -1,746
  -2,379
  -3,174
  -4,149
  -5,321
  -6,706
  -8,312
  -10,149
  -12,220
  -14,527
  -17,070
  -19,846
  -22,852
  -26,081
  -29,530
  -33,192
  -37,063
  -41,140
  -45,418
  -49,896
  -54,574
  -59,452
  -64,531
  -69,816
  -75,311
  -81,022

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  39
  60
  89
  130
  183
  251
  337
  443
  570
  720
  894
  1,092
  1,317
  1,567
  1,842
  2,143
  2,468
  2,818
  3,192
  3,589
  4,008
  4,450
  4,913
  5,398
  5,905
  6,433
  6,984
  7,556
  8,151
  8,770
Adjusted assets (=assets-cash), $m
  39
  60
  89
  130
  183
  251
  337
  443
  570
  720
  894
  1,092
  1,317
  1,567
  1,842
  2,143
  2,468
  2,818
  3,192
  3,589
  4,008
  4,450
  4,913
  5,398
  5,905
  6,433
  6,984
  7,556
  8,151
  8,770
Revenue / Adjusted assets
  0.179
  0.167
  0.169
  0.169
  0.175
  0.171
  0.172
  0.174
  0.174
  0.172
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
  0.173
Average production assets, $m
  8
  12
  18
  26
  37
  50
  68
  89
  114
  145
  179
  219
  264
  315
  370
  430
  496
  566
  641
  721
  805
  894
  987
  1,084
  1,186
  1,292
  1,403
  1,518
  1,637
  1,762
Working capital, $m
  3
  5
  8
  11
  16
  22
  29
  38
  49
  62
  77
  94
  114
  136
  159
  185
  214
  244
  276
  310
  347
  385
  425
  467
  511
  556
  604
  654
  705
  759
Total debt, $m
  5
  11
  19
  31
  47
  67
  92
  123
  161
  205
  256
  314
  380
  454
  535
  623
  719
  822
  932
  1,048
  1,172
  1,301
  1,438
  1,580
  1,729
  1,885
  2,046
  2,215
  2,390
  2,572
Total liabilities, $m
  11
  18
  26
  38
  54
  74
  99
  130
  167
  212
  263
  321
  387
  461
  542
  630
  726
  829
  938
  1,055
  1,178
  1,308
  1,444
  1,587
  1,736
  1,891
  2,053
  2,221
  2,397
  2,578
Total equity, $m
  27
  42
  63
  91
  129
  177
  238
  313
  402
  508
  631
  771
  930
  1,106
  1,301
  1,513
  1,743
  1,990
  2,253
  2,534
  2,830
  3,141
  3,469
  3,811
  4,169
  4,542
  4,930
  5,335
  5,755
  6,192
Total liabilities and equity, $m
  38
  60
  89
  129
  183
  251
  337
  443
  569
  720
  894
  1,092
  1,317
  1,567
  1,843
  2,143
  2,469
  2,819
  3,191
  3,589
  4,008
  4,449
  4,913
  5,398
  5,905
  6,433
  6,983
  7,556
  8,152
  8,770
Debt-to-equity ratio
  0.170
  0.250
  0.310
  0.340
  0.360
  0.380
  0.390
  0.390
  0.400
  0.400
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.410
  0.420
  0.420
  0.420
  0.420
Adjusted equity ratio
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706
  0.706

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -412
  -608
  -882
  -1,254
  -1,746
  -2,379
  -3,174
  -4,149
  -5,321
  -6,706
  -8,312
  -10,149
  -12,220
  -14,527
  -17,070
  -19,846
  -22,852
  -26,081
  -29,530
  -33,192
  -37,063
  -41,140
  -45,418
  -49,896
  -54,574
  -59,452
  -64,531
  -69,816
  -75,311
  -81,022
Depreciation, amort., depletion, $m
  2
  2
  4
  5
  7
  10
  14
  18
  23
  29
  36
  44
  53
  63
  74
  86
  99
  113
  128
  144
  161
  179
  197
  217
  237
  258
  281
  304
  327
  352
Funds from operations, $m
  -411
  -605
  -878
  -1,249
  -1,739
  -2,369
  -3,160
  -4,131
  -5,299
  -6,677
  -8,276
  -10,105
  -12,167
  -14,464
  -16,996
  -19,760
  -22,752
  -25,968
  -29,401
  -33,048
  -36,902
  -40,961
  -45,221
  -49,680
  -54,337
  -59,193
  -64,251
  -69,512
  -74,984
  -80,670
Change in working capital, $m
  1
  2
  3
  3
  5
  6
  7
  9
  11
  13
  15
  17
  19
  22
  24
  26
  28
  30
  32
  34
  36
  38
  40
  42
  44
  46
  48
  50
  51
  54
Cash from operations, $m
  -412
  -607
  -880
  -1,252
  -1,743
  -2,375
  -3,168
  -4,140
  -5,310
  -6,690
  -8,291
  -10,122
  -12,186
  -14,486
  -17,020
  -19,786
  -22,781
  -25,998
  -29,434
  -33,082
  -36,939
  -40,999
  -45,261
  -49,722
  -54,381
  -59,239
  -64,298
  -69,562
  -75,035
  -80,724
Maintenance CAPEX, $m
  -1
  -2
  -2
  -4
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -36
  -44
  -53
  -63
  -74
  -86
  -99
  -113
  -128
  -144
  -161
  -179
  -197
  -217
  -237
  -258
  -281
  -304
  -327
New CAPEX, $m
  -3
  -4
  -6
  -8
  -11
  -14
  -17
  -21
  -26
  -30
  -35
  -40
  -45
  -50
  -55
  -60
  -65
  -70
  -75
  -80
  -84
  -89
  -93
  -97
  -102
  -106
  -111
  -115
  -120
  -124
Cash from investing activities, $m
  -4
  -6
  -8
  -12
  -16
  -21
  -27
  -35
  -44
  -53
  -64
  -76
  -89
  -103
  -118
  -134
  -151
  -169
  -188
  -208
  -228
  -250
  -272
  -294
  -319
  -343
  -369
  -396
  -424
  -451
Free cash flow, $m
  -416
  -613
  -889
  -1,264
  -1,759
  -2,396
  -3,195
  -4,175
  -5,353
  -6,743
  -8,355
  -10,198
  -12,275
  -14,589
  -17,138
  -19,921
  -22,932
  -26,168
  -29,622
  -33,290
  -37,167
  -41,249
  -45,533
  -50,016
  -54,699
  -59,582
  -64,667
  -69,957
  -75,458
  -81,175
Issuance/(repayment) of debt, $m
  5
  6
  9
  12
  16
  20
  25
  31
  37
  44
  51
  58
  66
  73
  81
  88
  96
  103
  110
  117
  123
  130
  136
  143
  149
  155
  162
  168
  175
  182
Issuance/(repurchase) of shares, $m
  423
  622
  902
  1,282
  1,784
  2,428
  3,234
  4,223
  5,411
  6,811
  8,435
  10,289
  12,378
  14,704
  17,265
  20,059
  23,081
  26,328
  29,793
  33,472
  37,359
  41,452
  45,745
  50,239
  54,932
  59,825
  64,920
  70,220
  75,731
  81,459
Cash from financing (excl. dividends), $m  
  428
  628
  911
  1,294
  1,800
  2,448
  3,259
  4,254
  5,448
  6,855
  8,486
  10,347
  12,444
  14,777
  17,346
  20,147
  23,177
  26,431
  29,903
  33,589
  37,482
  41,582
  45,881
  50,382
  55,081
  59,980
  65,082
  70,388
  75,906
  81,641
Total cash flow (excl. dividends), $m
  12
  16
  22
  30
  40
  52
  65
  79
  96
  113
  131
  150
  169
  188
  207
  226
  245
  263
  281
  299
  316
  332
  349
  365
  381
  398
  414
  431
  448
  466
Retained Cash Flow (-), $m
  -423
  -622
  -902
  -1,282
  -1,784
  -2,428
  -3,234
  -4,223
  -5,411
  -6,811
  -8,435
  -10,289
  -12,378
  -14,704
  -17,265
  -20,059
  -23,081
  -26,328
  -29,793
  -33,472
  -37,359
  -41,452
  -45,745
  -50,239
  -54,932
  -59,825
  -64,920
  -70,220
  -75,731
  -81,459
Prev. year cash balance distribution, $m
  102
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -309
  -607
  -880
  -1,252
  -1,744
  -2,376
  -3,170
  -4,144
  -5,316
  -6,699
  -8,304
  -10,139
  -12,209
  -14,515
  -17,057
  -19,832
  -22,836
  -26,065
  -29,512
  -33,173
  -37,044
  -41,119
  -45,396
  -49,874
  -54,550
  -59,427
  -64,505
  -69,789
  -75,283
  -80,993
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -296
  -555
  -766
  -1,031
  -1,352
  -1,724
  -2,141
  -2,590
  -3,053
  -3,512
  -3,943
  -4,327
  -4,642
  -4,873
  -5,008
  -5,040
  -4,969
  -4,800
  -4,544
  -4,215
  -3,832
  -3,412
  -2,975
  -2,540
  -2,122
  -1,734
  -1,384
  -1,080
  -822
  -610
Current shareholders' claim on cash, %
  19.4
  4.2
  0.9
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

FINANCIAL RATIOS  of  Accelerate Diagnostics (AXDX)

Valuation Ratios
P/E Ratio -11.3
Price to Sales 0
Price to Book 9.5
Price to Tangible Book
Price to Cash Flow -14
Price to Free Cash Flow -13.5
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -59.5%
Ret/ On Assets - 3 Yr. Avg. -52.8%
Return On Total Capital -62.6%
Ret/ On T. Cap. - 3 Yr. Avg. -55.4%
Return On Equity -62.6%
Return On Equity - 3 Yr. Avg. -55.4%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AXDX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AXDX stock intrinsic value calculation we used $4.177 million for the last fiscal year's total revenue generated by Accelerate Diagnostics. The default revenue input number comes from 0001 income statement of Accelerate Diagnostics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AXDX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AXDX is calculated based on our internal credit rating of Accelerate Diagnostics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Accelerate Diagnostics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AXDX stock the variable cost ratio is equal to 5425%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $55 million in the base year in the intrinsic value calculation for AXDX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Accelerate Diagnostics.

Corporate tax rate of 27% is the nominal tax rate for Accelerate Diagnostics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AXDX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AXDX are equal to 116.1%.

Life of production assets of 2.1 years is the average useful life of capital assets used in Accelerate Diagnostics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AXDX is equal to 50%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $118.704 million for Accelerate Diagnostics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 51.218 million for Accelerate Diagnostics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Accelerate Diagnostics at the current share price and the inputted number of shares is $0.7 billion.

RELATED COMPANIES Price Int.Val. Rating
BRKR Bruker 32.16 23.13  sell
TMO Thermo Fisher 237.69 199.97  hold
BDX Becton Dickins 240.04 1,279.12  str.buy
PACB Pacific Biosci 7.61 0.16  str.sell
ILMN Illumina 319.51 182.51  sell
TTOO T2 Biosystems 4.70 0.01  str.sell

COMPANY NEWS

▶ Accelerate Diagnostics: 3Q Earnings Snapshot   [05:12PM  Associated Press]
▶ Accelerate Diagnostics: 2Q Earnings Snapshot   [04:17PM  Associated Press]
▶ Accelerate Diagnostics: 1Q Earnings Snapshot   [May-09-18 05:40PM  Associated Press]
▶ Accelerate Diagnostics reports 4Q loss   [Feb-15-18 04:52PM  Associated Press]
▶ What Are Accelerate Diagnostics Key Strengths?   [Jan-15-18 09:02AM  Market Realist]
▶ Stocks With Rising Relative Strength: Accelerate Diagnostics   [Dec-06-17 03:00AM  Investor's Business Daily]
▶ Accelerate Diagnostics Meets 80-Plus Relative Strength Rating Benchmark   [Dec-01-17 03:00AM  Investor's Business Daily]
▶ Accelerate Diagnostics reports 3Q loss   [Nov-02-17 05:36PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.